Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India.
Sinha SD, Biswas G, Bheemareddy BR, Chary S, Thakur P, Jain M, Maksud T, Pawar S, Chatterjee K, Voonna MK, Goel A, Puligundla KC, Lakshmaiah KC, Talluri L, Vattipalli R, Kakkunnath S. Sinha SD, et al. Among authors: chary s. Cancer Inform. 2023 Jun 1;22:11769351231177277. doi: 10.1177/11769351231177277. eCollection 2023. Cancer Inform. 2023. PMID: 37313371 Free PMC article.
Efficacy and safety of fixed-dose combination of Bilastine-Montelukast in adult patients with allergic rhinitis: a phase III, randomized, multi-center, double-blind, active controlled clinical study.
Sinha SD, Perapogu S, Chary S S, Ramesh S, Bakshi J, Singh A, Ahmed AK, Mohan Reddy B, Panapakam M, Talluri L, Vattipalli R. Sinha SD, et al. Among authors: chary s s. J Asthma. 2023 Nov;60(11):2014-2020. doi: 10.1080/02770903.2023.2209175. Epub 2023 May 31. J Asthma. 2023. PMID: 37140964
Efficacy and Safety of Molnupiravir in Mild COVID-19 Patients in India.
Sinha S, N K, Suram VK, Chary SS, Naik S, Singh VB, Jain MK, Suthar CP, Borthakur S, Sawardekar V, Sk N, Reddy N, Talluri L, Thakur P, Reddy M, Panapakam M, Vattipalli R. Sinha S, et al. Among authors: chary ss. Cureus. 2022 Nov 14;14(11):e31508. doi: 10.7759/cureus.31508. eCollection 2022 Nov. Cureus. 2022. PMID: 36532902 Free PMC article.
Correction to: Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: chary s. Neurotherapeutics. 2022 Sep;19(5):1686. doi: 10.1007/s13311-022-01286-9. Neurotherapeutics. 2022. PMID: 36175782 Free PMC article. No abstract available.
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
Miller TM, Cudkowicz ME, Genge A, Shaw PJ, Sobue G, Bucelli RC, Chiò A, Van Damme P, Ludolph AC, Glass JD, Andrews JA, Babu S, Benatar M, McDermott CJ, Cochrane T, Chary S, Chew S, Zhu H, Wu F, Nestorov I, Graham D, Sun P, McNeill M, Fanning L, Ferguson TA, Fradette S; VALOR and OLE Working Group. Miller TM, et al. Among authors: chary s. N Engl J Med. 2022 Sep 22;387(12):1099-1110. doi: 10.1056/NEJMoa2204705. N Engl J Med. 2022. PMID: 36129998 Free article. Clinical Trial.
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M, Farahany NA, Harrington EA, Chen W, Mitchell AA, Ferguson T, Chew S, Gedney L, Oakley S, Heo J, Chary S, Fanning L, Graham D, Sun P, Liu Y, Wong J, Fradette S. Benatar M, et al. Among authors: chary s. Neurotherapeutics. 2022 Jul;19(4):1248-1258. doi: 10.1007/s13311-022-01237-4. Epub 2022 May 18. Neurotherapeutics. 2022. PMID: 35585374 Free PMC article. Clinical Trial.
75 results